Willingness to pay for eliminating the risk of being infected by blood-borne diseases in regular replacement treatment for patients with haemophilia

Willingness to pay for eliminating the risk of being infected by blood-borne diseases in regular replacement treatment for patients with haemophilia

Hemophilia is a set of lifelong bleeding disorders linked to the X chromosome. Standard treatment for patients with severe hemophilia is intensive replacement therapy with intravenous injection of coagulation factor concentrates to prevent spontaneous recurrent joint bleed. In the 1980s, many hemop...

Full description

Bibliographic Details
Main Authors: Sara Olofsson, Katarina Steen Carlsson, Erik Berntorp, Emmelie Persson, Flemming Axelsen, Ulf Persson
Format: Article
Language:English
Published: University of Oslo 2016-08-01
Series:Nordic Journal of Health Economics
Subjects:
willingness to pay
hemophilia
recombinant factor VIII concentrates
regular replacement treatment
chained approach
preferences
Online Access:https://journals.uio.no/NJHE/article/view/990

Internet

https://journals.uio.no/NJHE/article/view/990

Similar Items